Association of hospital volume with survival but not with postoperative mortality in glioblastoma patients in Belgium
Dimitri Vanhauwaert(AZ Delta), Cindy De Gendt, Dario Di Perri(Cliniques Universitaires Saint-Luc), Steven De Vleeschouwer(KU Leuven), Tom Boterberg(Ghent University Hospital), Katrijn Vanschoenbeek, Raf Sciot(KU Leuven), Paul M. Clément(Universitair Ziekenhuis Leuven), Gregory Coucke, Geert Silversmit
Cited by 6
Related Papers
Lomustine and Bevacizumab in Progressive Glioblastoma
|New England Journal of Medicine|2017|994
Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034
|Journal of Clinical Oncology|2009|573
Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study
|The Lancet Oncology|2016|504
Phase I/IIa Study of Cilengitide and Temozolomide With Concomitant Radiotherapy Followed by Cilengitide and Temozolomide Maintenance Therapy in Patients With Newly Diagnosed Glioblastoma
|Journal of Clinical Oncology|2010|445
Imatinib Mesylate in Advanced Dermatofibrosarcoma Protuberans: Pooled Analysis of Two Phase II Clinical Trials
|Journal of Clinical Oncology|2010|401